CD4+CD161+ T lymphocytes infiltrate crohn's disease-associated perianal fistulas and are reduced by anti-TNF-α local therapy

International Archives of Allergy and Immunology

Volumn 161, Issue 1, 2013, Pages 81-86

  Maggi, Laura ^a   Capone, Manuela ^a   Giudici, Francesco ^a   Santarlasci, Veronica ^a   Querci, Valentina ^a   Liotta, Francesco ^a   Ficari, Ferdinando ^a   Maggi, Enrico ^a   Tonelli, Francesco ^a   Annunziato, Francesco ^a   Cosmi, Lorenzo ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

CD161; Crohn's disease; Lymphocytes; Th1; Th17

Indexed keywords

ADALIMUMAB; GAMMA INTERFERON; INTERLEUKIN 17;

ADULT; ANUS FISTULA; ARTICLE; CD4+ CD161+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CROHN DISEASE; CYTOKINE PRODUCTION; EFFECTOR CELL; FEMALE; HELPER CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOMODULATION; LYMPHOCYTIC INFILTRATION; MALE; PERIPHERAL LYMPHOCYTE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; TH1 CELL; TH17 CELL; CD3+ T LYMPHOCYTE; CD4+CD161+ T LYMPHOCYTE; DRUG EFFICACY; FLOW CYTOMETRY; INFLAMMATORY INFILTRATE; LOCAL THERAPY; OPPORTUNISTIC INFECTION;

ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL, HUMANIZED; CD4-POSITIVE T-LYMPHOCYTES; CROHN DISEASE; FEMALE; FLOW CYTOMETRY; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY B; RECTAL FISTULA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84871192596     PISSN: 10182438     EISSN: 14230097     Source Type: Journal    
DOI: 10.1159/000343467     Document Type: Article

References (18)

1. Abraham C, Cho JH: Inflammatory bowel disease. N Engl J Med 2009; 361:2066-2078.
2. Romagnani P, Annunziato F, Baccari MC, et al: T cells and cytokines in Crohn's disease. Curr Opin Immunol 1997; 9: 793-799. (Pubitemid 28062262)
3. Annunziato F, Cosmi L, Santarlasci V, et al: Phenotypic and functional features of human Th17 cells. J Exp Med 2007; 204: 1849-1861. (Pubitemid 47240944)
4. Cosmi L, De Palma R, Santarlasci V, et al: Human interleukin-17-producing cells originate from a CD161+ CD4+ T-cell precursor. J Exp Med 2008; 205: 1903-1916.
5. Maggi L, Santarlasci V, Capone M, et al: CD161 is a marker of all human IL-17-pro-ducing T-cell subsets and is induced by RORC. Eur J Immunol 2010; 40:2174-2181.
6. D'Haens GR, Panaccione R, Higgins PD, et al: The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response? Am J Gastroenterol 2011; 106: 199-212.
7. Asteria CR, Ficari F, Bagnoli S, et al: Treatment of perianal fistulas in Crohn's disease by local injection of antibody to TNF-alpha accounts for a favourable clinical response in selected cases: a pilot study. Scand J Gastroenterol 2006; 41:1064-1072. (Pubitemid 44385064)
8. Pikarsky AJ, Gervaz P, Wexner SD: Perianal Crohn disease: a new scoring system to evaluate and predict outcome of surgical intervention. Arch Surg 2002; 137:774-777. (Pubitemid 34743162)
9. Strober W, Fuss IJ: Proinflammatory cyto-kines in the pathogenesis of inflammatory bowel diseases. Gastroenterology 2011; 140: 1756-1767.
10. Fouser LA, Wright JF, Dunussi-Joannopoulos K, et al: Th17 cytokines and their emerging roles in inflammation and autoimmuni-ty. Immunol Rev 2008; 226: 87-102.
11. Chen Z, O'Shea JJ: Th17 cells: a new fate for differentiatiating helper T cells. Immunol Res 2008; 41:87-102.
12. Cosmi L, Cimaz R, Maggi L, et al: CD4+ CD161+ T cells showing transient nature of the Th17 phenotype are present in the syno-vial fluid from patients with juvenile idio-pathic arthritis. Arthritis Rheum 2011; 63: 2504-2515.
13. Olsen T, Rismo R, Cui G, Goll R, et al: TH1 and TH17 interactions in untreated inflamed mucosa of inflammatory bowel disease, and their potential to mediate the inf la mmation. Cytokine 2011; 56: 633-640.
14. Sandborn WJ, Feagan BG, Fedorak RN, et al: A randomized trial of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. Gastroenterology 2008; 135: 1130-1141.
15. Santarlasci V, Maggi L, Capone M, et al: Rarity of human T helper 17 cells is due to reti-noic acid orphan receptor-dependent mechanisms that limit their expansion. Immunity 2012; 36: 201-214.
16. Aravena O, Pesce B, Soto L, et al: Anti-TNF therapy in patients with rheumatoid arthritis decreases Th1 and Th17 cell populations and expands IFN-7-producing NK cell and regulatory T cell subsets. Immunobiology 2011; 216:1256-1263.
17. Keane J, Gershon S, Wise RP, et al: Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001; 345:1098-1104.
18. Poggioli G, Laureti S, Pierangeli F, et al: Local injection of infliximab for the treatment of perianal Crohn's disease. Dis Col Rectum 2005; 48:768-774. (Pubitemid 40880725)